

CAYMAN ISLANDS STOCK EXCHANGE

PCI PENN UK HOLDCO LTD (THE "ISSUER")

18 December 2015

For immediate release

The board of directors of the Issuer wish to announce the following:

Change in directors

Mitchell Eric Blumenfeld resigned as a director of the Issuer on 12 May 2015.

Joseph Edward Whitters was appointed as a director of the Issuer on 14 July 2015. Mr. Whitters has been part of the Frazier's Growth Buyout team and has a deep understanding of finance and governance issues at rapidly growing healthcare services companies. Before Frazier, Mr. Whitters held various finance positions of increasing responsibility at First Health (FHCC), a managed care organization he helped take public as Chief Financial Officer. The business address for Mr. Whitters is Suite 3200, 601 Union Street, Seattle, Washington, USA 98101.

Nathan Robert Every, M.D. was appointed as a director of the Issuer on 14 July 2015. Dr. Every is a general partner of Frazer Healthcare Partners and member of its Growth Buyout team, specializing in middle-market healthcare companies. A cardiologist by training, Dr. Every has been with Frazer Healthcare Partners since 1999. The business address for Dr. Every is Suite 3200, 601 Union Street, Seattle, Washington, USA 98101.

Alan David Frazier was appointed as a director of the Issuer on 14 July 2015. As founder and Chairman of Frazier Healthcare Partners, has a long track record of successful investments in both Life Sciences and Growth Buyout companies. Mr. Frazer founded Frazier Healthcare Partners in 1991 and has led the firm in raising seven institutional funds and managing more than \$2 billion in assets. The business address for Mr. Frazer is Suite 3200, 601 Union Street, Seattle, Washington, USA 98101.

Phillip Cummins was appointed as a director of the Issuer on 12 May 2015. As Principal for QIC's Global Private Equity team, his focus is on venture and growth co-investments. From 2005 to 2006, he was a Business Director with Wilson HTM, focused on Australian middle market growth companies. Previously, Mr. Cummins was a healthcare investment banker in San Francisco, working with Deutsche Bank and Thomas Weisel Partners between 1998 and 2005. The business address for Mr. Cummins is Level 5, Central Plaza Two, Brisbane, Queensland, Australia 4000.

Tadataka Yamada, M.D. was appointed as a director of the Issuer on 22 July 2015. Dr. Yamada is a venture partner on Frazier Healthcare Partners' life sciences team, providing strategic guidance to portfolio companies. Dr. Yamada has an extensive history serving in executive leadership and

director roles for some of the world's leading healthcare-related institutions, including most recently, roles as President of the Bill & Melinda Gates Global Health Program, as Chief Medical & Scientific Officer and Board member of Takeda Pharmaceuticals, and as Chairman of R&D and Board member of GlaxoSmithKline. Dr. Yamada holds degrees from NYU School of Medicine and Stanford University and includes Knight Commander of the Most Excellent Order of the British Empire (KBE) among his many professional, academic and honorary titles. The business address for Dr. Yamada is Suite 3200, 601 Union Street, Seattle, Washington, USA 98101.

Change in auditor

PricewaterhouseCoopers LLP, 2001 Market St., Suite 1800, Philadelphia, Pennsylvania USA 19103 was appointed as auditor to the Issuer on 1 July 2015.

For further information in relation to the above announcement please contact Nicola Murray at the office of Ogier (Tel: +1 345 815 1784 or nicola.murray@ogier.com).